Insider Movements at Jazz Pharmaceuticals Plc Monitored by Knox Daily
December 16, 2023
🌥️Trending News
Knox Daily has been closely monitoring the insider movements of Jazz Pharmaceuticals ($NASDAQ:JAZZ) plc. The company has a diversified portfolio of products to treat a range of conditions and diseases, including sleep disorders, cancer, inflammation and genitourinary conditions. The company’s products have received approval from the U.S. Food and Drug Administration and the European Medicines Agency.
The company’s directors, officers and other insiders have been actively buying and selling shares in the company and these movements have been tracked by Knox Daily. Insider movements can be an important indicator of a company’s direction and performance and Knox Daily’s tracking of Jazz Pharmaceuticals plc’s insider moves can provide investors with valuable insights into the company’s future prospects.
Price History
The stock of Jazz Pharmaceuticals Plc opened at $125.6 and closed at $123.0, a decrease of 2.0% from the previous closing price of 125.5. This performance indicates the possibility of insider movements at the company and hence the need for close monitoring. The market is watching closely to see if there will be further changes in the stock price due to these movements. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Jazz Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 3.79k | 79.95 | 10.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Jazz Pharmaceuticals. More…
| Operations | Investing | Financing |
| 1.27k | -589.24 | -185.35 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Jazz Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 11.2k | 7.71k | 55.44 |
Key Ratios Snapshot
Some of the financial key ratios for Jazz Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 18.5% | -2.7% | 5.0% |
| FCF Margin | ROE | ROA |
| 22.9% | 3.4% | 1.1% |
Analysis
At GoodWhale, we provide analysis of financials to help investors make informed decisions. By looking at the Star Chart for JAZZ PHARMACEUTICALS, we can see that the company is strong in asset, growth, and profitability, and weak in dividend. JAZZ PHARMACEUTICALS also has a high health score of 7/10, making it able to sustain future operations even in times of crisis. All in all, we classify JAZZ PHARMACEUTICALS as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Such a company might be interesting for investors who are looking for stable returns with limited risk. They may also be interested in investing in a company that is well-positioned to weather difficult times. In short, investors looking for moderate growth and long-term stability should consider JAZZ PHARMACEUTICALS. More…
Peers
The company has a diversified portfolio of products in central nervous system, hematology/oncology, inflammation and other therapeutic areas. Jazz Pharmaceuticals‘ competitors include Nurix Therapeutics Inc, Incyte Corp, and Poxel SA.
– Nurix Therapeutics Inc ($NASDAQ:NRIX)
Nurix Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on harnessing the body’s own natural mechanisms to regulate protein function for the treatment of cancer and other diseases. The company’s lead product candidate is a first-in-class, orally available, small molecule inhibitor of the proteasome, which is in development for the treatment of relapsed or refractory multiple myeloma. Nurix was founded by Robert L. Gould, Ph.D. and Bruce A. Cohen, M.D. in December 2001 and is headquartered in San Francisco, CA.
– Incyte Corp ($NASDAQ:INCY)
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. The company’s market cap is 15.34B as of 2022 and its ROE is 9.54%. Incyte’s products include Jakafi, Iclusig, and Jakavi. Jakafi is used to treat myelofibrosis and polycythemia vera, two rare blood disorders. Iclusig is used to treat leukemias, including chronic myeloid leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia. Jakavi is used to treat myelofibrosis, polycythemia vera, and essential thrombocythemia.
– Poxel SA ($LTS:0RA2)
Poxel SA is a French pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of diabetes and obesity. The company has a market capitalization of 43.37 million as of 2022 and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.
Summary
Jazz Pharmaceuticals plc is a biopharmaceutical company that specializes in the development and commercialization of innovative treatments for serious medical conditions. With recent insider movements taking place, investors are paying close attention to the company’s performance. Analysts believe that Jazz Pharmaceuticals has a strong pipeline of novel drugs in the development stage and could be headed for great success. Financial results from the past few quarters have been positive with revenues increasing and gross profit margins widening.
The company has also made strategic investments to expand its portfolio of products and build a long-term growth strategy. Moreover, the company has a strong balance sheet and cash flow position that can help it invest in research and development activities. All in all, investors are optimistic about the prospects of Jazz Pharmaceuticals and are encouraged by its long-term growth potential.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
